Aramis Biosciences

Executive Summary

Aramis Biosciences is a clinical-stage immuno-ophthalmology biopharmaceutical company headquartered in San Diego, CA, dedicated to developing disease-modifying therapies for ocular surface diseases, with an initial focus on dry eye disease (DED). Founded in 2018, the company's lead candidate, A197, is a novel, first-in-class topical immunomodulatory agent currently undergoing Phase II clinical trials. DED represents a large and underserved market, with current treatments primarily addressing symptoms rather than underlying pathophysiology. A197's unique mechanism of action targets immune-mediated inflammation, offering potential for disease modification and differentiation from existing therapies. The company is privately held and has not disclosed detailed financials, but its focused pipeline and early clinical progress position it as an emerging player in the ophthalmology space. Successful Phase II results could unlock significant value through partnership or further development.

Upcoming Catalysts (preview)

• Q4 2026Phase II top-line data readout for A197 in dry eye disease40% success
• H2 2027Potential strategic partnership or licensing deal35% success
• Q1 2027Initiation of Phase IIb/III trial design or regulatory guidance50% success